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S_mimary Mutation and overexpression are the main activating mechanisms for the ras family of genes in
human cancer and the variable tandem repeat (VTR) located at the 3' end of H-ras has been associated with
this risk. In the present study, we have analysed the relative levels ofexpression of H-ras mRNA in 26 samples
of squamous cell carcinomas of the head and neck (SCCHN) by competitive reverse transcription-polymerase
chain reaction (competitive RT-PCR) and also investigated whether there is an association between ras
expression and alterations in the 3'-VTR region. In addition, we have studied the incidence of point mutations
in codon 12 of H-ras, codons 12 and 13 of K-ras and codon 61 of N-ras in 120 SCCHN samples. Our results
indicate that only two samples carry mutations, both of which are located in codon 12 of K-ras, but that
overexpression of the H-ras proto-oncogene is a frequent event in SCCHN [54% (14/26)] and is associated
with a favourable prognosis: 3 of 14 patients with H-ras overexpression have died, whereas 9 of 12 patients
with low levels of H-ras expression have died. We have also undertaken an analysis of these results together
with our previous investigations on microsatellite instability and loss of heterozygosity in SCCHN, but no
associations were found. We therefore conclude that ras mutations are an infrequent event in the progression
of the SCCHN in the Western world, whereas overexpression of the H-ras proto-oncogene is a common event.
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Genetic alterations in oncogenes and tumour-suppressor
genes have been impLicated in the iniation, promotion and
progression of cancer. The ras family of genes (H-, K- and
N-ras) encode a 21 kDa membrane protein (p21) which pos-
sesses GTPase activity and participates in a signal transduc-
tion pathway (Boguski and McCormick, 1993). Hotspots for
ras mutations are found in codons 12, 13 and 61, causing the
mutant protein to lose its ability to exchange GTP with
GDP; thus, it binds GTP with higher affinity and remains
activated (Barbacid, 1987). Mutational activation of the ras
family genes has been reported in a wide range of human
malignancies: 90% of pancreatic and 40% of colonic car-
cinomas harbour a mutation in K-ras and 50% of bladder
carcinomas have H-ras mutations (Bos, 1989). Overexpres-
sion of the normal alleles of ras genes can also transform cell
lines in vitro (Spandidos and Wilkie, 1984) and have been
reported in a number of cancers, such as breast and colon
cancer and squamous cell carcinoma of the head and neck
(SCCHN) (Field and Spandidos, 1990). High levels of p21
have been postulated to activate other genes (including
oncogenes such as myc, jun and fos) that are functionally
downstream of ras and regulate normal cell growth and
differentiation.
In addition to mutations and overexpression of ras genes,
other genetic alterations have been described and shown to
be associated with the development of human tumours. Loss
of heterozygosity (LOH) of the H-ras locus has been
reported in a number of carcinomas (Shiraishi et al., 1987;
Garcia et al., 1989; Vachtenheim et al., 1994), including
SCCHN (Howell et al., 1989; Sheng et al., 1990; Kiaris et al.,
1994), and it has been proposed that the normal H-ras gene
may possess tumour-suppressor as well as oncogene functions
(Spandidos et al., 1990). Recently, we reported that genetic
instability of a repetitive element which is located within
intron 1 of H-ras is associated with the nodal status of
patients with SCCHN (Kiaris et al., 1994). These observa-
tions indicate that ras genes play a complex role in car-
cinogenesis and may have a number of different functions
during the development of neoplasia.
The ras family of genes has been studied in SCCHN by
several investigators, mainly at the level of mutations,
mRNA and protein expression. A high incidence of muta-
tions in ras genes has only been reported in SCCHN patients
from India (Saranath et al., 1991) and is most likely to be
associated with the chewing of tobacco. Although ras muta-
tions are considered to be rare events in the Western world
(Field, 1992, for a review), overexpression of ras family genes
has been reported by a number ofinvestigators. Spandidos et
al. (1985) demonstrated elevated levels of H-ras and K-ras
mRNA in all of the 14 SCCHN samples studied, but no
correlation was found with clinicopathological parameters
(Field et al., 1986) while Sheng et al. (1990) reported elevated
levels of H-ras mRNA in lymph node metastases and
primary tumours from SCCHN. An immunohistochemical
analysis has been undertaken by Field et al. (1992), who
demonstrated that levels of expression of ras p21 in 69
SCCHN patients correlated with a favourable clinical out-
come. However, two Japanese studies were at variance with
these results. Azuma et al. (1987) found that high levels of
H-ras correlated with poor prognosis in SCCHN patients,
and Tsuji et al. (1989) failed to find any association between
the overexpression of H-ras and the clinical outcome. The
results of these two Japanese groups are not in agreement
with those from the UK, a difference that may be attributed
to different environmental risk factors. Recently, the levels of
H-ras p21 in primary laryngeal cancers were studied by an
Italian group using Western blotting and, even though
elevated levels were found, no association with any clinical
parameters was reported (Scambia et al., 1994).
In the present study, we have analysed the overexpression
of H-ras mRNA in SCCHN using competitive reverse trans-
cription PCR (Foley et al., 1993; Kotsinas et al., 1994).
Briefly, this technique consists of the reverse transcription of
specific mRNAs and their co-amplification by PCR with an
internal control which shares the same primer sites within the
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target cDNA, a process that results in increased sensitivity
and accuracy. We have also investigated the i of
mutations in ras genes by PCR followed by in frag-
ment length polymophism (RFLP) in 120 SCCHN patients.
The results of this study were also analysed with relation to
our previous findings of loss of heterozygosity and genetic
instability of the H-ras gene.
Matasiak ad owbo
Specimens
A total of 120 tumour specmens were collected from car-
cinomas of the head and neck at the Department of Otor-
hnolangoky , Royal Liverpo l Univy Hospital, and
Maxillofacial Unit, Walton HospitaL Liverpol. Tumour
samples obtained from surgical were frozen in
lquid nitrogen and stored at - 70C.
DNA and RNA extracton
Genomic DNA and total RNA were extracted from tumour
speimens using the Nucleon II DNA extraction kit (Scotlab)
and the TRIzol reagent (Gibco BRL), iespectively, following
the manufcter's instructions. Genomic DNA were
stored at 4CC and total RNA mples at 20C.
Olgonuckotide priners andPCRampl*fxcation
The oligonucleotide primers used for amlficaton of codon
12 of H-ras, codons 12 and 13 of K-ras and codon 61 of
N-ras are shown in Table I. PCR reactions were performed
in a final volume of 50;1 and contained 35 mM magnesum
chloride, 100mm Tris-HCI pH 8.3, 500mm potassium
chloride 0.1% gelatin, 200mM of each dNTP, 200ng of
DNA, 100 ng of each primer and 1.25 units of Taq
pomrase (Advanced Biotechnologies). The ampltion
conditions for each pair of primers were as follows:
(a) H-ras. Denaturation at 95YC for 40 s, primer an ling at
61-C for 45 s and extension at 72C for 45 s; 28-30
cycles; PCR product size 419 bp.
(b) K-ras. Denaturation at 94C for 40 s, primer annealing at
60C for 45s and extension at 72C for 50 s; 28-35
cycles, PCR product size 157 bp.
(c) N-ras. Denaturation at 94C for 30 s, primer an ling at
58-C for 40s and primer extension at 72C for 30s;
28-35 cycl PCR product size 65 bp.
All PCR reactions were initially denatured for 5min at
95'C.
RFLP anaysis ofras mutations
(1) H-ras codon 12: 10-20 pi of the amplification product
was dig overnight with 40 units of MspI.
(2) K-ras codons 12 and 13: 10-20 p1 of the ampification
product was dised for 3 h with 20 units of BstNI
(codon 12) and another aliquot of 20 units of HphI
(codon 13, Gly to Asp).
(3) N-ras codon 61: 10-20 i1 of the amplifation product
was digest ovenight with 40 units of MscI.
The incubation temperatures were 60'C for BstNI and
37C for the rmaining enzymes. The digestion products were
354bp and 385 bp for H-ras codon 12 and 113 bp and
142 bp for K-ras codon 12, normal and mutant alleles respec-
tively. The normal codon 61 N-ras allele produced a 44bp
band, while the mutant allele remained 65 bp in size and the
mutant (Gly to Asp) codon 13 K-ras allde produced a
115 bp band compared with a normal PCR product of
157 bp. Restriction enzymes were supplied by New England
Biolabs. The digestion products were analysed on 2%
agarose gels (H-ras codon 12, K-ras codon 12 and 13) or on
10% polyacrylamide gels (N-ras codon 61) and visuaised
under UV illumination after staining with ethidium
bromide.
Competitive reverse transcrption PCR (RT-PCR) and RNA
quantiuion
This procedure has been described in detail elsewhere (Kot-
sinas et al., 1994). Briefly, the competitor sequence (cloned
within a plasmid) has been derived by an internal deletion of
the PCR product of the same set of primers, applied to
genomic DNA. This results in a fragment which is smaler
than the genomic DNA product, but larger than the cDNA
product; thus, it shares the same primer sites and serves in
the PCR reaction as a competitor. A 200 ng aiquot of total
RNA was reverse transcribed in a 50 id reaction (10 mM
Tris-HCI pH 8.3, 50 mM p9tassium chloride, 1 mM man-
ganese chloride, 200mM dNTP, 200ng of antsense primer
and 2.5 units Tth polymerase) for 15 min. PCR amplification
of cDNA was then performed by adding 50 1d of 75 mm
Tris-HCl pH 9.0, 20 mM ammonium sulphate, 1.5 mM
magnesium chloride, 0.01% Tween 20 (w/v), 0.75 mM EGTA
200 ng of sense primer and using the PCR programme
previously described for 28 cyces. The number of cycles was
decied after preliminary experiments showed that the PCR
reaction remained in the exponential phase at this ime. A
standard curve was derived from seri dilutions of total
RNA (0.1 jIg, 0.2 jg, 0.5 jg, 1.0 jg and 2.0 jg) mixed with
50pg of competitor plasmid (Figure 1). The PCR products
were analysed in a 6% polyacrylamide gel stained with either
silver or ethidium bromide. The quantity and quality of
target RNA was determined by ampliiation of P-actin
-- Competitor
- Target
Standard curve of H-ras mRNA by the RT-PCR
amay. Fifty poga of tor DNA was co-amplifid with
2.0 g (lane 1), 1.0 jg (lane 2), 0.5 jag (lane 3), 0.2 jg (kan 4) and
0.1 jag (lane 5) of total RNA. M, marker= pBR322/HarIl.
Tae I Primers used for ras analysis
H-ras codon 12 5'-GACGGAATATAAGCI3GGTGG3'
3'-TAACTACCCCTCTGCACGGA-5'
K-ras codons 12 and 13 5'-ACTGAATATAAACTTGTGGTAGTTGGACCT-3'
5'-TCAAAGAATGGTCCTGGACC-3'





5'-CTCCTTAATGTCACGCACGATTTC-3'M -m ziso, gMuctausiEy of H-ir in SMHNI
H Kiars et a I
mRNA (548 bp) using the reaction mixture described above
and the following amplification conditions: 1 min at 95-C,
1 min at 58-C and 1 min at 72-C for 28 cycles. The quantity
of RNA used in all experimental amplifications of H-ras
mRNA was thus previously normalised by the prior amplifi-
cation of A-actin mRNA from each sample. The interpreta-
tion of the expression levels of H-ras using competitive
RT-PCR (using the aforementioned competitor plasmid) is
calculated using the following ratio: (target vs competitor in
the tumour tissue) to (target vs competitor in the normal
tissue). Amplification and quantitation of H-ras mRNA was
performed at least twice for each sample and produced
similar results each time.
Reds
Among the 120 samples analysed, only two were found to
contain a ras mutation, both of which were in codon 12 of
K-ras (Figure 2). No mutations were found in codon 13 of
K-ras, codon 12 of H-ras, or codon 61 of N-ras. These
results are in agreement with previous studies, which show
less than 5% ras mutations in SCCHN in the Western world
(Tables H and III). As there were only two positive samples
with mutations out of 120 SCCHN tested, no analysis with
the clinicopathological parameters was undertaken.
Twenty-six SCCHN samples (five oropharynx, 11 hypo-
pharynx, five oral, five larynx) were analysed for aberrant
expression of H-ras mRNA. Twenty of the 26 SCCHN sam-
ples exhibited elevated expression of H-ras in the tumour
tissue, ranging from 1.1-to 8.1-fold expression (Table IV,
Figures 3 and 4). Since tumour cells are characterised by high
rates of proliferation, small increases in the level of expres-
sion of the H-ras gene would be expected as being represen-
tative of a cell kinetic system in which the ras signal trans-
duction pathway is activated. However, four samples (184,
360, 225 and 1092) showed slghtly lower levels of the H-ras
mRNA in their tumour tissue. Thus, we arbitrarily divided
Fge 2 PCR-RFLP assay for the detection of K-ras codon 12
mutations in SCCHN. Lane 1, marker pUC18/HaeI; lane 2,
undigested PCR product; lane 3, control DNA sample from cell
line SW 480 which harbours a homozygous mutation at codon 12
ofK-ras, lanes 4, 7 and 8, normal samples; lanes 5 and 6, mutant
sampks.





12, 13, 61 12, 13, 61 12, 13, 61
Nwnber of 348 137 191 269 190 70 107 42 190
samples tested
Number of 6 0 0 2 0 2 0 0 0
mutations
Per cent 1.7 0 0 0.7 0 2.8 0 0 0
mutations
Table n Cumulative results on ras mutations in SCCHN
Ras gene Number of
and codon specinens Mutations (codon) Reference
India




K-ras-12 33 6(12) Kuo et al. (1994)
Western world
H-ras-12,61 54 2(12) Sheng et al. (1990)
K-ras-12,13,61 28 0
N-ras-12,61 28 0
H-ras-12 37 2 Rumsby et al. (1990)
K-ras-12 37 0
N-ras-12 37 0
K-ras-12 42 0 Hirano et al. (1991)
H-ras-12,13,61 30 0 Chang et al. (1991)
K-ras-12,13,61 30 2(61)
N-ras-12,13,61 30 0
H-ras-12,13,61 28 1(12) Warnakulasuriya et al. (1992)
H-ras-12,13,61 67 0 Clark et al. (1993)
H-ras-12,13,61 12 1(12) Yeudall et al. (1993)
K-ras-12,13,61 12 0
N-ras-12,13,61 12 0
H-ras-12 120 0 Present study
K-ras-12,13 120 2(12)
N-ras-61 120 0s , -nmi d H-in SC
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Tae IV H-ras exprresson in SCCHN
H-ras
mRNA VTR TNM Nodes at
SanpI kveW istai&y Sit?b Histology sare' pathlogy
350 8.1 HP MD mI +
338 7.5 + HP MD I -
355 6.5 0 WD in +
228 5.1 OP PD IV ND
358 3.3 - 0 MD IV +
302 3.3 + HP MD m -
366 3.1 HP WD I ND
353 2.4 0 MD IV -
365 2-2 OP MD IV +
339 2.2 - L MD I -
343 2.1 - 0 MD IV +
359 1.9 - L MD I -
351 1.7 - L MD IV -
218 1.5 - HP PD IV +
337 1.4 HP WD m +
336 1.4 + HP WD m -
192 1.4 HP PD IV +
1161 1.3 - 0 MD IV ND
305 1.2 - HP MD IV +
361 1.1 HP MD n +
348 1.1 OP PD HI +
370 1.0 OP PD Ill ND
1092 0.9 OP WD III -
360 0.9 + L MD IV +
225 0.8 - L MD i -
184 0.8 + HP PD iI +
'Levels ofH-rasmRNA areexpressed as the ratio ofthekve in the
tumour vs the normal tiue. "OP, oropharynx; HP, hypopharynx 0,
oral; L, larynx 'WI, MD and PD, wel,n modately and poorly
differentiated SCC respectively. *TNM staging (UICC, 1978). ND, no
data.
the tumour samples by their H-ras mRNA levels of expres-
sion into two groups; patients in the first and second groups
exhibited < 1.5- and > 1.5-fold expression of H-ras, respec-
tively, compared with normal tissue. Thus 14 ofthe 26 (54%)
SCCHN specimens tested showed overexpression of H-ras
mRNA, but no association was found with site, histology,
TNM staging or positive nodes at pathology (Table IV). An
association was found, however, between the klvels ofexpres-
sion of H-ras and the clinical outcome; 9 of the 12 patients
with no evidence of H-ras overexpression have died, whereas
3 of the 14 patients with elevated expression of the H-ras
proto-oncogene are dead (log-rank analysis, x2 = 4.27,
P<0.05). This result should be treated with caution as a
number of these patients have been followed up for under 1
year (median 13 months, range 1-87 months).
PCR amplification of the 3'-VTR region was only possible
in 14 of the 26 patient samples owing to technical difficulties
with some ofthe specimens. In 5 of 14 (36%) SCCHN paired
samples, a different pattern was observed in the tumour
specimens compared with their normal tissu counterparts,
indicating genetic instability of the VTR region. (Some of
these results have been previously reported in Kiaris et al.,
1994.) No association with clinicopathological paraiitrs
was demonstrated. An interesting observation was that,
among the five SCCHN tumour specmens with VTR genetic
instability, four had altered levels of H-ras mRNA compared
with their normal tisse; two had lower levels (0.8 and 0.9)
and two had higher levels (7.5 and 3.3). This may indicate
that, at least in a certain number of patients, deregulation in
the expression of H-ras is due to destabilisation of the VTR
region of the gene.
Head and neck cancers are the sixth commonest cancers in
the world but have a wide geographical variation which is
most likely due to specific environmental risk factors (Vokes






Flgwe 3 Representae exampes of H-rw o expess in
specime numbers 228 and 353, i by the RT-PCR
assay. Number 370 sents a specme with no H-ras overep-
resson, showing equal lvs of expressio n the normal and
tumour saple e PCR product was siv stained and scan-
ned using the UVP image analysis system. The upper arrow
indcates the competitor H-rwas and the lower arrow the target
H-ras.
N T N T N T N T
b
365 366 358 355
Flge 4 H-ras verexpreson in tumour specimens 365, 366,
358 and 355. The PCR protu was quntifie sg the UVP
agealysis systn after stining wI brmidei. (a)
Competitor H-rar; (b) target H-ras.
mutations in the Western world compared with SE Asia and
India. In the Western world, ras mutations in SCCHN are
very rare (<5%), whereas in India 35% of SCCHN patients
harbour a mutation in H-ras, and this has been associated
with tobacco chewing (Saranath et al., 1991). In Taiwan,
18% of oral cancer patients investigted were found to have
a K-ras mutation, and these patients chew betel quid but do
not use tobacco (Kuo et al., 1994). In this study, 120 samples
were analysed for mutations in codon 12 of H-ras, codons 12
and 13 of K-ras and codon 61 of N-ras, but only two of
these samples (1.8%) contained ras mutations, both of which
were found in codon 12 of K-ras. This is the largest analysis
to date of ras mutations in SCCHN and the results confirm
that ras mutations in SCCHN are rare in the Western world
(Table HII).
The expression of H-ras mRNA in SCCHN was inves-
tigated by competitive RT-PCR, which is a fast and sen-
sitive technique for the interpretation of the klvels of specific
tniscripts in cells or tissue. This is the first report to our
knowledge that employs competitive RT-PCR for the inves-
tigation of H-ras mRNA expreson in tumour tissues. In the
past, Northern blot and dot blot hybridisation techniques
have been used, but they have the disadvantages of being
ime-co ing and requiring the use of radioactivity. The
primers used for H-ras cDNA amplification lie in adjacent
exons of the H-ras gene, and thus it is possible to dis-M hisabilbt dH1s inSCCHN
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criminate against contamination of the target RNA with
genomic DNA. This particular feature of the amplification
reaction and the co-amplification of the internal control
(pGEM22OH-ras) produces increased specificity and accuracy
of results (Kotsinas et al., 1994).
Significntly elevated levels of H-ras mRNA were found in
14 of the 26 (54%) SCCHN specimens tested, and in four
(15%) patients the levels of H-ras mRNA were lower in the
tumour than in the normal tissue. No association was found
between the levels of expression of H-ras and the site of the
tumour, TNM staging, histology or the nodal status of the
patients, suggesting that, although overexpression of the H-
ras proto-oncogene is associated with the development of
SCCHN, alterations in other oncogenes or tumour-
suppressor genes (TSGs) may be more important for the
progression of this disease. The four TNM stage I tumours
investigated in this present study all exhibited elevated levels
of H-ras mRNA (>1.5-fold), which may indicate that the
overexpression of this proto-oncogene is important in the
early stages of the disease. In vitro studies have suggested
that H-ras overexpression is associated with morphological
transformation, but tumorigenicity is also greatly increased
when it is accompanied by the overexpression of K-ras and
N-ras (Coleman et al., 1994). The association of H-ras
overexpression in SCCHN with a favourable prognosis is in
agreement with an earlier immunohistochemical analysis of
ras p21 in 69 SCCHN samples (Field et al., 1992).
We have previously reported LOH at the H-ras locus
(Kiaris et al., 1994). Three of the specimens that exhibited
LOH were used in the present study, but no association
between LOH at H-ras and overexpression of the gene was
found. This result is in agreement with Sheng et al. (1990),
who also demonstrated no association between overexpres-
sion of mRNA and LOH at the H-ras locus in 11 SCCHN
specimens. However, the transcriptional activation of H-ras
still remains a puzzle. The lack of a TATA box and the
presence of a CAAT box in the GC-rich promoter at the 5'
end of the gene reveals similarities with other housekeeping
genes (Breathnach and Chambon, 1981; Honkawa et al.,
1987). If overexpression of H-ras was due solely to the high
proliferative status of cancer cells, then normalisation of the
quantity of H-ras mRNA with actin mRNA (which is also a
housekeeping gene) would equalise any differences between
normal and tumour tissue from the same patient. However,
the relative levels of expression ranged from 0.8 to 8.1, and
this probably indicates that specific genetic alterations in
particular tumour samples activate or inactivate H-ras proto-
oncogene expression.
The VTR region in the 3' end of H-ras possesses
differential enhancer activity (Spandidos and Holmes, 1987)
and may divide the SCCHN population into certain sub-
groups which have an increased risk of developing cancer
(Krontiris et al., 1993). Since we have already reported that
instability occurs in a repetitive element (HRMS) located in
intron 1 of H-ras (Kiaris et al., 1994), we considered that
genetic instability in the 3'-VTR region of H-ras may also be
a possibility, thus resulting in the generation of new VTR
alleles within the tumours of patients. This may explain, at
least in a certain number of samples, the deregulation of
H-ras gene. Indeed, we did find that 5/14 (36%) patients
exhibited 3'-VTR instability, confirming the suggestion that
the H-ras VTR is a potential target for instability. However,
the levels of H-ras mRNA were not associated with ins-
tability of the 3'-VTR region; two tumours exhibited overex-
pression (7.5 and 3.3 times) and two had relatively lower
levels of H-ras mRNA (0.8 and 0.9 times). This may indicate
that instability of the 3'-VTR region could influence the
regulation of the H-ras gene in vivo, as previously proposed
after in vitro experiments (Green and Krontiris, 1993). How-
ever, a combined analysis of H-ras expression and instability
of the VTR region in a larger number of patients is required
to extend this observation.
Our study confirms the proposal that ras gene mutations
are rare in SCCHN in the Western world but that overexp-
ression of H-ras is associated with the development of
SCCHN, however, the interpretation of this finding remains
unclear. Further investigations should aim to clarify the
significance of elevated transcription of the H-ras proto-
oncogene and also to distinguish the mechanism(s) that
results in the aberrant expression of H-ras in SCCHN.
Finally, the present study illustrates the power of the com-
petitive RT-PCR as a fast and sensitive technique for
screening a relatively large number of samples for specific
mRNA expression.
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